PATENT CLAIM ANALYSIS

Application Number: 15909787
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-03
Patent Classification: ["424", "152100"]

Abstract:
Disclosed herein are methods of preventing incidence of a migrainous or non-migrainous post-ictal headache, and/or at least one secondary symptom associated with a migrainous post-ictal headache in a subject comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided.

Claim (Index 17):
The method of  claim 16 , wherein the dose is an initial dose and the method further comprises administering to the subject an additional dose of about 225 mg of the monoclonal antibody once per month in each of the two months subsequent to the month in which the initial dose is administered to the subject.

Metadata:
- Claim Count in Document: 55.0
- Percentile: 90.0
- Lexical Diversity: 1.34146
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14711705', '15879900', '14664715', '15712444', '14719015']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5973877180490054
- 35 USC 102 Novelty (BERT): 0.5782074326684157
- Combined Prediction Score: 0.5954696895109465
- Mean Citation Score: 492.9413579999999
- Max Citation Score: 507.0279
- Similarity Product: 347.22390237350464

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test